Nirrin Technologies appointed S.T. Japan as its exclusive distribution partner for the TALOS^TM protein quantitation system in Japan. The Japanese company will purchase a TALOS demonstration system, establishing local evaluation capabilities that will allow prospective customers throughout Japan to assess the technology using their own samples and workflows.

“Japan is one of the world’s leading centers for biopharmaceutical innovation and manufacturing,” according to Bryan Hassell, PhD, CEO of Nirrin Technologies. “S.T. Japan has built a strong reputation for helping customers adopt advanced analytical technologies through deep technical expertise and exceptional support.”

TALOS is designed to replace traditional variable pathlength UV workflows with a simpler fixed-path near-infrared measurement approach, noted Hassell. By directly measuring absorption from the peptide backbone, TALOS enables rapid protein quantitation across a wide concentration range without dilution, protein-specific calibration models, extinction coefficient determination, or manual pathlength adjustment, he explained.

“TALOS represents a unique advancement in protein quantitation, enabling rapid, consistent measurements with operational simplicity. These capabilities make it particularly well-suited for modern bioprocessing workflows, from early process development through GMP manufacturing,” said Takao Nakagawa, president, S. T. Japan. “As Japan’s biopharmaceutical industry continues to expand and evolve, TALOS has the potential to make a significant impact, driving efficiencies and reducing complexity across the drug development and manufacturing continuum.”

The post Nirrin Technologies and S.T. Japan Partner on Next-Gen Protein Quantitation Tech appeared first on GEN – Genetic Engineering and Biotechnology News.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. There’s a lot of great reporting to share today, so be sure to read all the way through the newsletter. We won’t have a newsletter tomorrow, Juneteenth, so I’ll talk to you again on Monday.

Read the rest…

​Read More

Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.